MedPath

The PURI-HF (Air Purifiers on Heart Failure) Trial

Not Applicable
Recruiting
Conditions
Heart Failure
Interventions
Other: Placebo Air Filter
Other: AirOk Air Purifier
Registration Number
NCT05230784
Lead Sponsor
NYU Langone Health
Brief Summary

Indoor air pollution and fine mode particulate matter with an aerodynamic diameter smaller than 2.5 micrometers (PM2.5) is a major contributor to global morbidity and mortality, particularly due to cardiovascular disease. This project aims to demonstrate the efficacy, feasibility and effectiveness of portable air filters in improving indoor PM2.5 levels and improving functional capacity of heart failure patients with reduced ejection fraction in India. The findings from the project will add to existing knowledge of innovative and scalable strategies to improve environmental and cardiovascular health worldwide.

The overall objective of this study is to demonstrate the efficacy, feasibility, and effectiveness of portable air filters in improving indoor PM2.5 levels and improving functional capacity of heart failure patients with reduced ejection fraction in India.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
600
Inclusion Criteria
  • Adults ≥ 18 years of age diagnosed with HF with a reduced ejection fraction of ≤ 40% within the last six months in NYHA class II-IV.
Exclusion Criteria
  • listed for a cardiac transplant
  • history of CRT device implantation in last 3 months
  • on oxygen therapy
  • with severe pulmonary disease
  • participants unable to ambulate

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
EGAPA Air PurifierPlacebo Air FilterAir purifier is installed in participants' households by the research team. Twice per year, participants will wear a GPS as well as a backpack containing a particulate matter 2.5 (PM2.5) personal exposure monitor for a 24-hour monitoring period.
HEPA Air PurifierAirOk Air PurifierAir purifier is installed in participants' households by the research team. Twice per year, participants will wear a GPS as well as a backpack containing a particulate matter 2.5 (PM2.5) personal exposure monitor for a 24-hour monitoring period.
Primary Outcome Measures
NameTimeMethod
Change in Distance WalkedBaseline, 12 months

The distance in meters will be recorded during a 6-minute walk test (MWT)

Secondary Outcome Measures
NameTimeMethod
Change in pro B-type natriuretic peptide (Pro-BNP) LevelsBaseline, 12 months
Change in Systolic Blood Pressure (SBP)Baseline, 12 months
Change in Diastolic Blood Pressure (DBP)Baseline, 12 months
Change in Number of HospitalizationsBaseline, 12 months
Change in Heart RateBaseline, 12 months

Trial Locations

Locations (3)

All India Institute of Medical Sciences (AIIMS)

🇮🇳

Delhi, Punjab, India

Centre for Chronic Disease Control (CCDC)

🇮🇳

Thiruvananthapuram, Kerala, India

Public Health Foundation of India (PHFI)

🇮🇳

Ludhiāna, Punjab, India

© Copyright 2025. All Rights Reserved by MedPath